To The Moon

$ECHOIQ LTD(EIQ.AU)$ It has been 5-6 days since the announcement by EIQ that FDA didn’t approve its application. EchoSolv HF is off for now. 501(k) is supposed to be an easier and faster way to bring EchoSolv HF into the market. However, FDA has apparently cut that path off with the way the objection was raised. Obviously EIQ can still put EchoSolv HF to the market by using a different path (De Novo) for FDA approval. It’s not a preferred way since it would require a lot more time and effort. At least another 12-18 months would probably be required. Given this new unexpected uncertainty, the big crash in its stock price was expected.

This is a genuinely difficult situation, and the honest answer is that there is no "safe" price in the traditional sense. The investment case has fundamentally shifted from a near-term regulatory catalyst to a long-duration, execution-heavy story. What looks like a bargain could easily become a value trap if the FDA pathway remains unclear.

The Core Problem: The 510(k) Route Is Now Uncertain

The FDA's "Not Substantially Equivalent" (NSE) determination is not a standard rejection; it means the agency does not accept EchoSolv HF as equivalent to any existing predicate device. Management still believes a 510(k) pathway exists and will engage the FDA directly, but analysts like Petra Capital do not believe resolution will be "quick or simple". A revised submission or a shift to a more rigorous De Novo pathway could easily consume 12-18 months.

Revenue Sustainability and Partner Risk

EchoSolv AS is the only revenue-generating asset, and the company reported just A10 million Pro Medicus investment tranche was explicitly contingent on HF clearance and is now off the table. While these partners have not walked away, the commercial urgency for HF has evaporated, which weakens Echo IQ's leverage in those relationships.

A Framework for Thinking About Price

Rather than a specific safe price, here is a framework based on what the market is now pricing:

The "Cash and AS Optionality" Floor

Echo IQ held cash pile of A$105M. The AS business, while barely generating revenue, has FDA clearance and a growing US footprint. This provides a loose valuation anchor.

The "Broken Thesis" Discount

Bell Potter cut its price target by 82% to 30¢ and moved to a sell recommendation, anticipating delays of "many months, if not years". This represents the bear case where HF is effectively shelved and the company burns cash trying to fix the regulatory issue. If you believe the HF opportunity is permanently impaired, 30-50¢ would be the implied range.

The "Delayed but Intact" Scenario

Ord Minnett and Morgans maintained Buy ratings with targets around A$1.55-1.85 before the rejection. Those targets are now stale. However, if you assign high probability to eventual HF clearance within 12-18 months, the current price of around 57-64¢ could be seen as a deep discount to a future value. The risk is that this scenario requires you to hold through continued uncertainty, potential cash burn on revised studies, and the possibility of further negative news.

The single most important catalyst now is a substantive update on the FDA engagement that names a specific pathway and a rough timeline. Until that happens, the stock will likely trade on AS commercial momentum and cash runway alone. A safe entry point would logically be after that clarity emerges, even if the price is higher, because the range of outcomes would be narrower.

The question is whether Echo IQ can convert its clinical validation (99.5% sensitivity, 91% specificity for HF) into commercial traction for AS while it fixes the HF regulatory issue. If you believe that is achievable, the current price reflects significant pessimism. If you believe the FDA setback signals deeper issues with the submission or the company's regulatory capabilities, the crash was justified and further downside is possible.

To understand EIQ’s option if it’s to use the other FDA’s pathway, I will explain briefly what that is.

The De Novo Connection

This is where the patent and regulatory paths collide:

· De Novo requires proving your device is novel (no predicate) and has reasonable safety/effectiveness.

· Patent requires proving the invention is new and non-obvious.

The FDA's "Not Substantially Equivalent" finding doesn't grant a patent, but if the FDA is saying "there's no comparable tool," that actually supports the argument that the device is novel for patent purposes. However, the USPTO is a separate agency with different standards. A patent is not a shortcut to FDA approval, and an FDA rejection does not automatically mean the patent is dead—but it does signal that the technical claims may be harder to defend.

What the Patent Filings Actually Show

The evidence confirms Echo IQ has been building a patent portfolio around its core algorithms, not just relying on regulatory exclusivity:

· December 2023: Priority lodgement of a provisional patent specifically covering the proprietary Heart Failure algorithm

· 2024-2025: Granted patents for "Systems and Methods for AI-Assisted Echocardiography", with the abstract explicitly covering methods for predicting heart failure from echocardiograph data, including imputation of unpopulated data fields and probability outputs

· Q1 2026: A further 10 new patents filed across the US, Europe, Australia, and major Asia-Pacific/Middle Eastern markets, plus four new trademarks

So the HF algorithm is not just a regulatory artifact—it has actual IP protection covering the method of processing echocardiograph data to predict heart failure .

Why This Reshapes the De Novo Concern

If De Novo makes EchoSolv HF the first predicate, competitors could file a 510(k) pointing to it and get cleared faster, essentially free-riding on Echo IQ's regulatory investment.

But with granted patents on the core method:

· A competitor cannot practice the patented method without infringing, regardless of FDA clearance

· The De Novo grant only provides a regulatory shortcut, not a legal right to use the patented technology

· This means Echo IQ's first-mover advantage is protected by two independent barriers: regulatory (De Novo predicate) and legal (patent infringement)

The Remaining Risk

The patents protect the method, but the De Novo summary will still publish the intended use and key technological characteristics . A competitor could potentially develop a non-infringing alternative that achieves the same clinical result through different algorithmic means, and then use the De Novo predicate for faster 510(k) clearance. Patents raise the cost of competition; they don't eliminate it.

But that's a far better position than having no patent protection at all. The cash pile of A$105M serves as a good buffer for now pending the company’s next step. Having said that, the current share price is not undervalued. Similarly, it is not overpriced either.

Final thoughts

For me, and me only, the company upside potential is still high. If EchoSolv HF is not given an eventual go ahead, the company share price could suffer another 50% drop. Conversely, if FDA eventually gives the go-ahead, $2 is within its reach. Even so, the question remains if you are willing to spend the next 12-18 months, or longer for that to happen. I will leave the answer for you as it is all about individual choices and situations.

@TigerStars @Daily_Discussion @Tiger_comments @CaptainTiger @TigerClub